Lentiviral vectors efficiently transfer genes into a broad spectrum of cells and tissues, including non-dividing cells and stem cells. Lentiviruses integrate their viral genome into the host chromosome, which is the basis for virus latency as well as stable transgene expression. A rather novel development is the use of lentivectors to transfer transgenes in oocytes and early embryos to generate transgenic animals, a technology also known as lentiviral transgenesis. Lentiviral transgenesis has been shown to be highly efficient in many different species, including mouse, rat, pig, bovine, and even birds. Thus, lentiviral transgenesis has the potential to become a versatile and widespread transgenic technology. The aim of this chapter is to cover important practical aspects of lentiviral transgenesis, including vector preparation, gene delivery into the early embryos and lentiviral RNA interference.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/978-1-59745-471-1_21 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PD1-Targeted Transgene Delivery to Treg Cells.
Viruses
December 2024
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Achieving the precise targeting of lentiviral vectors (LVs) to specific cell populations is crucial for effective gene therapy, particularly in cancer treatment where the modulation of the tumor microenvironment can enhance anti-tumor immunity. Programmed cell death protein 1 (PD-1) is overexpressed on activated tumor-infiltrating T lymphocytes, including regulatory T cells that suppress immune responses via FOXP3 expression. We developed PD1-targeted LVs by incorporating the anti-PD1 nanobody nb102c3 into receptor-blinded measles virus H and VSV-G glycoproteins.
View Article and Find Full Text PDFMacrophage Inhibitor Clodronate Enhances Liver Transduction of Lentiviral but Not Adeno-Associated Viral Vectors or mRNA Lipid Nanoparticles in Neonatal and Juvenile Mice.
Cells
November 2024
Great Ormond Street Institute of Child Health, University College London, London WC1E 1EH, UK.
Recently approved adeno-associated viral (AAV) vectors for liver monogenic diseases haemophilia A and B are exemplifying the success of liver-directed viral gene therapy. In parallel, additional gene therapy strategies are rapidly emerging to overcome some inherent AAV limitations, such as the non-persistence of the episomal transgene in the rapidly growing liver and immune response. Viral integrating vectors such as in vivo lentiviral gene therapy and non-viral vectors such as lipid nanoparticles encapsulating mRNA (LNP-mRNA) are rapidly being developed, currently at the preclinical and clinical stages, respectively.
View Article and Find Full Text PDFEnhancing Gene Delivery in NB-4 Cells: Overcoming Transduction and Selection Challenges.
Cells
November 2024
Cellular Signalling Laboratory, Department of Biomedical Sciences, University of Bologna, 40126 Bologna, Italy.
Efficient gene transduction and cell viability are critical factors in genetic manipulation for research and therapeutic purposes. In this study, we explored the challenges associated with transducing the NB-4 cell line, a well-established model for acute promyelocytic leukemia (APL), using lentiviral vectors. While the initial transduction efficiency in NB-4 cells reached approximately 30%, we observed a significant decrease in cell viability, a phenomenon not observed in other acute leukemia cell lines such as THP-1 cells.
View Article and Find Full Text PDFGeneration of Biologically Contained Marburg Virus.
Methods Mol Biol
November 2024
KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute, Laboratory of Clinical and Epidemiological Virology, Leuven, Belgium.
Wild-type Marburg virus (MARV) can only be handled in biosafety level 4 facilities. By removing an essential gene from the virus genome, deficient virus particles can be generated that are only capable of replication if the missing gene product is provided in trans. As a result, these viruses are restricted to specific cell lines, making them safe to handle at lower biosafety levels.
View Article and Find Full Text PDFDevelopment of HIV-1 vectors pseudotyped with envelope proteins of other retroviruses.
Virology
January 2025
Research Group Medical Biotechnology & Bioengineering, Faculty of Applied Natural Sciences, TH Köln - University of Applied Sciences, Campusplatz 1, 51379, Leverkusen, Germany. Electronic address:
In the past three decades, human immunodeficiency virus type 1 (HIV-1)-derived vectors were evolved and became indispensable to transduce therapeutic genes into a range of different target cell types to facilitate a variety of gene therapeutic strategies. To achieve this, i) the biosafety profile of the vectors was incrementally enhanced and ii) the CD4-restricted tropism mediated by the envelope proteins (Env) of the parental virus needed to be directed towards recruitment of other receptors expressed on the desired target cells. Here, a closer look is first taken at the development of vector components and the mechanisms of Env incorporation into particles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!